Genomic Technologies: What are the Practical Uses for Cancer – By Dr Larry Croft
|When:||Thursday, June 11, 2015 11:00am until 12:15pm (followed by lunch)|
|Where:||Medical Library Auditorium, Faculty of Medicine and Health Sciences, UPM|
In this talk, Dr Larry will recount the history of mutation targeted cancer therapy. The first successful targeted drug was the Novartis drug Glivec, against the BCR-ABL genomic translocation found in chronic myelogenous leukemia. During his time working at Novartis, he discovered similar chromosomal translocation driver mutations in many solid tumours. Solid tumours at the time (early 2000s) weren’t thought to harbor translocation events, let alone driver mutations. During the intervening years a whole palette of targeted drugs has become available, many from the Novartis “Kinase Factory”. These drugs and many more new ones hold great promise for solid and liquid tumours, but much remains to be done to bring them into general beneficial use for cancer patients.
|Notes:||RSVP to attend|